EMEA Reverses Negative Decision On GTC’s Transgenic Antithrombin ATryn
This article was originally published in The Pink Sheet Daily
Executive Summary
GTC Biotherapeutics expects to file a BLA in the U.S. for recombinant human antithrombin in the first half of 2007.